DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)

3 Months Ended

Mar. 31, 2022

Acquisitions, Divestitures and Other Arrangements [Abstract]

Disposal Groups, Including Discontinued Operations

The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).

	Three Months Ended March 31,
	Net Proceeds(a)				Divestiture (Gains)/Losses				Royalty Income
Dollars in Millions	2022		2021		2022		2021		2022		2021
Diabetes Business	$	172	$	164	$	—	$	—	$	(170)	$	(134)
Mature Products and Other	225		16		(211)		—		(1)		(1)
Total	$	397	$	180	$	(211)	$	—	$	(171)	$	(135)

(a)    Includes royalties received subsequent to the related sale of the asset or business.

Licensing and Other Arrangements

The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, up-front licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.

	Three Months Ended March 31,
Dollars in Millions	2022		2021
Keytruda* royalties	$	(221)	$	(192)
Tecentriq* royalties	(25)		(22)
Contingent milestone income	(41)		—
Amortization of deferred income	(12)		(15)
Other royalties	(7)		(3)
Total	$	(306)	$	(232)